董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul Edick | 男 | Chief Executive Officer and Chairman of the Board | 66 | 682.66万美元 | 未持股 | 2022-04-12 |
| Dawn Halkuff | 女 | Director | 51 | 29.05万美元 | 20.75 | 2022-04-12 |
| Marla Persky | 女 | Director | 66 | 32.65万美元 | 23.55 | 2022-04-12 |
| Jeffrey Sherman | 男 | Director | 67 | 28.55万美元 | 37.44 | 2022-04-12 |
| John H. Johnson | 男 | Director | 64 | 27.65万美元 | 90.54 | 2022-04-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul Edick | 男 | Chief Executive Officer and Chairman of the Board | 66 | 682.66万美元 | 未持股 | 2022-04-12 |
| Beth Hecht | 女 | Chief Legal Officer and Corporate Secretary | 58 | 189.53万美元 | 99.77 | 2022-04-12 |
| Steven Prestrelski | 男 | Chief Scientific Officer | 58 | 未披露 | 未持股 | 2022-04-12 |
| Ken Johnson | 男 | Senior Vice President, Global Development and Medical Affairs | 59 | 105.84万美元 | 未持股 | 2022-04-12 |
| Steven M. Pieper | 男 | Chief Financial Officer | 45 | 187.41万美元 | 99.31 | 2022-04-12 |
| John Shannon | 男 | President and Chief Operating Officer | 60 | 504.26万美元 | 174.73 | 2022-04-12 |
董事简历
中英对照 | 中文 | 英文- Paul Edick
-
Paul Edick自2015年6月起在公司董事会工作。他目前是3G Advisors有限责任公司（3G Advisors, LLC，医药，医疗保健和医疗保健投资者团体的顾问公司，2007年创立）的经营合伙人。2010年7月-2014年11月Edick先生是Durata Therapeutics的首席执行官，2014年11月和Actavis plc NYSE： ACT合并。在那之前，Edick先生是Ganic Pharmaceuticals的首席执行官（2008-2010年）；MedPointe Healthcare 股份有限公司（MedPointe Healthcare Inc.）的首席执行官（2006-2008年）；MedPointe的药学运营总裁（2002-2006年）。Edick先生在NewLink Genetics股份有限公司（NewLink Genetics Inc. （NASDAQ： NLNK））和Circassia Ltd. （LSE： CIR.L）董事会工作（2011年起）。他拥有纽约克林顿汉弥尔顿林肯学院（Hamilton College in Clinton, NY）心理学学士学位。
Paul Edick has served as Xeris Pharmaceuticals, Inc. Chief Executive Officer since May 2021 in connection with the Strongbridge acquisition. Mr. Edick joined Xeris Pharmaceuticals, Inc. in January 2017 as President and Chief Executive Officer and was appointed as Chairman in June 2018. As of August 2020 Mr. Edick relinquished the President title he held at Xeris Pharmaceuticals, Inc. Previously, Mr. Edick was a founding partner of 3G Advisors, a consultancy firm to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014 Mr. Edick was the chief executive officer of Durata Therapeutics, Inc., a biopharmaceutical company, prior to its acquisition in November 2014. Prior to that, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from 2008 to 2010. Before that, from 2006 to 2008 Mr. Edick was chief executive officer of MedPointe Healthcare, Inc., a pharmaceutical company, and served as its president of pharmaceutical operations from 2002 to 2006. - Paul Edick自2015年6月起在公司董事会工作。他目前是3G Advisors有限责任公司（3G Advisors, LLC，医药，医疗保健和医疗保健投资者团体的顾问公司，2007年创立）的经营合伙人。2010年7月-2014年11月Edick先生是Durata Therapeutics的首席执行官，2014年11月和Actavis plc NYSE： ACT合并。在那之前，Edick先生是Ganic Pharmaceuticals的首席执行官（2008-2010年）；MedPointe Healthcare 股份有限公司（MedPointe Healthcare Inc.）的首席执行官（2006-2008年）；MedPointe的药学运营总裁（2002-2006年）。Edick先生在NewLink Genetics股份有限公司（NewLink Genetics Inc. （NASDAQ： NLNK））和Circassia Ltd. （LSE： CIR.L）董事会工作（2011年起）。他拥有纽约克林顿汉弥尔顿林肯学院（Hamilton College in Clinton, NY）心理学学士学位。
- Paul Edick has served as Xeris Pharmaceuticals, Inc. Chief Executive Officer since May 2021 in connection with the Strongbridge acquisition. Mr. Edick joined Xeris Pharmaceuticals, Inc. in January 2017 as President and Chief Executive Officer and was appointed as Chairman in June 2018. As of August 2020 Mr. Edick relinquished the President title he held at Xeris Pharmaceuticals, Inc. Previously, Mr. Edick was a founding partner of 3G Advisors, a consultancy firm to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014 Mr. Edick was the chief executive officer of Durata Therapeutics, Inc., a biopharmaceutical company, prior to its acquisition in November 2014. Prior to that, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from 2008 to 2010. Before that, from 2006 to 2008 Mr. Edick was chief executive officer of MedPointe Healthcare, Inc., a pharmaceutical company, and served as its president of pharmaceutical operations from 2002 to 2006.
- Dawn Halkuff
-
Dawn Halkuff自2018年4月以来一直担任我们的董事会成员。自2016年以来，Halkoff女士一直担任Therapeuticsmd，Inc.首席商务官在此之前，Halkuff女士曾在辉瑞公司（Pfizer，Inc.）担任多个高级职位，该公司是辉瑞消费者梦百合健康组织，也是其消费者全球领导团队的成员，包括担任高级副总裁，全球健康、Vice President、女性健康销售与市场营销和女性健康产品高级总监。在此之前，哈尔库夫女士是辉瑞公司（Pfizer&；8217；S）妇女健康部门销售与市场营销的商业负责人。Halkuff从2005年到2010年担任Weight Watchers International全球创新主管。Halkoff拥有University of Connecticut心理学学士学位和Pennsylvania State University工商管理硕士学位。
Dawn Halkuff has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Ms. Halkuff served as a member of the board of directors of Xeris Pharmaceuticals, Inc. beginning in April 2018. Since December 2021 Ms. Halkuff has served as the chief executive officer of Ideal Protein of America, Inc., a weight loss company. From November 2016 to September 2021 Ms. Halkuff has served as the chief commercial officer of TherapeuticsMD, Inc., a pharmaceutical company. Prior to that, Ms. Halkuff held numerous senior level positions at Pfizer Inc., a biopharmaceutical company, and the Pfizer Consumer Healthcare Wellness Organization and was a member of its Consumer Global Leadership Team, including in roles such as senior vice president, global wellness, vice president, women's health sales and marketing and senior director, women's health products. Prior to that, Ms. Halkuff was the commercial lead for sales and marketing of the Pfizer Women's Health Division. From 2005 to 2010 Ms. Halkuff was head of global innovation at Weight Watchers International. - Dawn Halkuff自2018年4月以来一直担任我们的董事会成员。自2016年以来，Halkoff女士一直担任Therapeuticsmd，Inc.首席商务官在此之前，Halkuff女士曾在辉瑞公司（Pfizer，Inc.）担任多个高级职位，该公司是辉瑞消费者梦百合健康组织，也是其消费者全球领导团队的成员，包括担任高级副总裁，全球健康、Vice President、女性健康销售与市场营销和女性健康产品高级总监。在此之前，哈尔库夫女士是辉瑞公司（Pfizer&；8217；S）妇女健康部门销售与市场营销的商业负责人。Halkuff从2005年到2010年担任Weight Watchers International全球创新主管。Halkoff拥有University of Connecticut心理学学士学位和Pennsylvania State University工商管理硕士学位。
- Dawn Halkuff has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Ms. Halkuff served as a member of the board of directors of Xeris Pharmaceuticals, Inc. beginning in April 2018. Since December 2021 Ms. Halkuff has served as the chief executive officer of Ideal Protein of America, Inc., a weight loss company. From November 2016 to September 2021 Ms. Halkuff has served as the chief commercial officer of TherapeuticsMD, Inc., a pharmaceutical company. Prior to that, Ms. Halkuff held numerous senior level positions at Pfizer Inc., a biopharmaceutical company, and the Pfizer Consumer Healthcare Wellness Organization and was a member of its Consumer Global Leadership Team, including in roles such as senior vice president, global wellness, vice president, women's health sales and marketing and senior director, women's health products. Prior to that, Ms. Halkuff was the commercial lead for sales and marketing of the Pfizer Women's Health Division. From 2005 to 2010 Ms. Halkuff was head of global innovation at Weight Watchers International.
- Marla Persky
-
Marla Persky自2018年4月以来一直担任我们的董事会成员。自2014年以来，Persky女士一直担任Womn，LLC（一家咨询和教练组织）的首席执行官兼总裁。从2005年到2013年，Persky女士担任勃林格殷格翰公司（Boehringer Ingelheim Corporation）的高级副总裁，总法律顾问兼公司秘书，该公司是一家制药公司。Persky女士还担任Text IQ，Inc.的顾问委员会和Ygeia Group，Inc.的董事会成员。Persky拥有Northwestern University言语科学B.S.S.学位和Washington University School of Law J.D.学位。
Marla Persky has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Ms. Persky served as a member of the board of directors of Xeris Pharmaceuticals, Inc. beginning in April 2018. Since 2014 Ms. Persky has served as the chief executive officer and president of WOMN LLC, a consulting and coaching organization. From 2005 to 2013 Ms. Persky was senior vice president, general counsel and corporate secretary of Boehringer Ingelheim Corporation, a pharmaceutical company and prior to that spent 19 years with Baxter International Inc. in both legal and business roles. Ms. Persky also serves on the board of directors of Revolo Biotherapeutics Limited and Panavance Therapeutics, Inc. - Marla Persky自2018年4月以来一直担任我们的董事会成员。自2014年以来，Persky女士一直担任Womn，LLC（一家咨询和教练组织）的首席执行官兼总裁。从2005年到2013年，Persky女士担任勃林格殷格翰公司（Boehringer Ingelheim Corporation）的高级副总裁，总法律顾问兼公司秘书，该公司是一家制药公司。Persky女士还担任Text IQ，Inc.的顾问委员会和Ygeia Group，Inc.的董事会成员。Persky拥有Northwestern University言语科学B.S.S.学位和Washington University School of Law J.D.学位。
- Marla Persky has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Ms. Persky served as a member of the board of directors of Xeris Pharmaceuticals, Inc. beginning in April 2018. Since 2014 Ms. Persky has served as the chief executive officer and president of WOMN LLC, a consulting and coaching organization. From 2005 to 2013 Ms. Persky was senior vice president, general counsel and corporate secretary of Boehringer Ingelheim Corporation, a pharmaceutical company and prior to that spent 19 years with Baxter International Inc. in both legal and business roles. Ms. Persky also serves on the board of directors of Revolo Biotherapeutics Limited and Panavance Therapeutics, Inc.
- Jeffrey Sherman
-
Jeffrey Sherman自2018年4月以来一直担任我们的董事会成员。自2009年以来，Sherman博士一直担任Horizon Pharma plc的首席医疗官和执行Vice President。Sherman博士是Strongbridge Biopharma plc的董事会成员，也是多个专业协会的成员，还是国家医学检验员委员会和美国内科委员会的外交官，并担任临床研究参与信息与研究中心（Center for Information and Research）顾问委员会成员。他曾在IDM Pharma Takeda Global研究与开发、Neopharm、Searle/Pharmacia和Bristol-Myers Squibb担任过职务，曾任药物信息协会主席。Sherman在Lake Forest College获得生物学学士学位，并在Rosalind Franklin University of Medicine and Science/The Chicago Medical School获得医学博士学位。Sherman博士完成了西北大学范伯格医学院（Northwestern University Feinberg School of Medicine）的实习和住院医师项目，在那里他目前担任兼职助理教授，以及加州大学旧金山分校（University of California San Francisco）的奖学金项目。
Jeffrey Sherman has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Dr. Sherman served as a member of the board of directors of Xeris Pharmaceuticals, Inc. beginning in April 2018. Since 2009 Dr. Sherman has served as the chief medical officer and executive vice president at Horizon Therapeutics plc., a biopharmaceutical company. Dr. Sherman also served on the board of directors of Strongbridge Biopharma plc, a biopharmaceutical company, prior to the acquisition by Xeris Pharmaceuticals, Inc. He is a member of a number of professional societies, a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine, and on the Board of Advisors of the Center for Information and Study on Clinical Research Participation CISCRP. He previously held positions at pharmaceutical companies such as IDM Pharma, Inc., Takeda Global Research and Development, NeoPharm Inc., G.D. Searle, LLC/Pharmacia Corporation, and Bristol-Myers Squibb and is past board chair of the Drug Information Association (DIA). - Jeffrey Sherman自2018年4月以来一直担任我们的董事会成员。自2009年以来，Sherman博士一直担任Horizon Pharma plc的首席医疗官和执行Vice President。Sherman博士是Strongbridge Biopharma plc的董事会成员，也是多个专业协会的成员，还是国家医学检验员委员会和美国内科委员会的外交官，并担任临床研究参与信息与研究中心（Center for Information and Research）顾问委员会成员。他曾在IDM Pharma Takeda Global研究与开发、Neopharm、Searle/Pharmacia和Bristol-Myers Squibb担任过职务，曾任药物信息协会主席。Sherman在Lake Forest College获得生物学学士学位，并在Rosalind Franklin University of Medicine and Science/The Chicago Medical School获得医学博士学位。Sherman博士完成了西北大学范伯格医学院（Northwestern University Feinberg School of Medicine）的实习和住院医师项目，在那里他目前担任兼职助理教授，以及加州大学旧金山分校（University of California San Francisco）的奖学金项目。
- Jeffrey Sherman has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Dr. Sherman served as a member of the board of directors of Xeris Pharmaceuticals, Inc. beginning in April 2018. Since 2009 Dr. Sherman has served as the chief medical officer and executive vice president at Horizon Therapeutics plc., a biopharmaceutical company. Dr. Sherman also served on the board of directors of Strongbridge Biopharma plc, a biopharmaceutical company, prior to the acquisition by Xeris Pharmaceuticals, Inc. He is a member of a number of professional societies, a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine, and on the Board of Advisors of the Center for Information and Study on Clinical Research Participation CISCRP. He previously held positions at pharmaceutical companies such as IDM Pharma, Inc., Takeda Global Research and Development, NeoPharm Inc., G.D. Searle, LLC/Pharmacia Corporation, and Bristol-Myers Squibb and is past board chair of the Drug Information Association (DIA).
- John H. Johnson
-
John H. Johnson，他曾一直担任Xeris Pharmaceuticals, Inc.董事（2013年11月以来）。他曾担任Dendreon Corporation的总裁和首席执行官（从2012年1月到2014年8月）。他此前曾担任Savient Pharmaceuticals公司（一家制药公司）的首席执行官兼董事（从2011年1月到2012年1月）。此前，他曾担任Eli Lilly and Company的肿瘤学单位的高级副总裁兼总裁（从2009年11月到2011年1月）。他也曾担任ImClone Systems Incorporated公司的首席执行官（从2007年到2009年11月），也曾任职于ImClone公司的董事会（直到2008年被Eli Lilly公司收购）。加入ImClone公司之前，他曾担任Johnson & Johnson公司的全球生物制药单位的公司集团主席（从2005年到2007年）、Ortho Biotech Products LP 和Ortho Biotech Canada单位的总裁（从2003年到2005年）、 CNS, Pharmaceuticals Group战略单位的全球副总裁（从2001年到2003年）。他目前担任Tranzyme公司和Dendreon Corporation的董事会主席，以及Cempra公司（一个制药公司临床阶段）的董事。他也担任the Pharmaceutical Research and Manufacturers of America的董事会成员，以及the Health Section Governing Board of Biotechnology Industry Organization的成员。他持有the East Stroudsburg University of Pennsylvania的学士学位。
John H. Johnson has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Mr. Johnson served on the board of directors of Strongbridge since March 2015 and as the Chief Executive Officer of Strongbridge from July 2020 to October 2021. Since March 2022 Mr. Johnson has served as Chief Executive Officer and Director of Reaction Biology Corp., a biotechnology company. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. Mr. Johnson is also a member of the board of directors of Verastem, Inc. also known as Verastem Oncology and Autolus Therapeutics. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr.Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization. - John H. Johnson，他曾一直担任Xeris Pharmaceuticals, Inc.董事（2013年11月以来）。他曾担任Dendreon Corporation的总裁和首席执行官（从2012年1月到2014年8月）。他此前曾担任Savient Pharmaceuticals公司（一家制药公司）的首席执行官兼董事（从2011年1月到2012年1月）。此前，他曾担任Eli Lilly and Company的肿瘤学单位的高级副总裁兼总裁（从2009年11月到2011年1月）。他也曾担任ImClone Systems Incorporated公司的首席执行官（从2007年到2009年11月），也曾任职于ImClone公司的董事会（直到2008年被Eli Lilly公司收购）。加入ImClone公司之前，他曾担任Johnson & Johnson公司的全球生物制药单位的公司集团主席（从2005年到2007年）、Ortho Biotech Products LP 和Ortho Biotech Canada单位的总裁（从2003年到2005年）、 CNS, Pharmaceuticals Group战略单位的全球副总裁（从2001年到2003年）。他目前担任Tranzyme公司和Dendreon Corporation的董事会主席，以及Cempra公司（一个制药公司临床阶段）的董事。他也担任the Pharmaceutical Research and Manufacturers of America的董事会成员，以及the Health Section Governing Board of Biotechnology Industry Organization的成员。他持有the East Stroudsburg University of Pennsylvania的学士学位。
- John H. Johnson has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Mr. Johnson served on the board of directors of Strongbridge since March 2015 and as the Chief Executive Officer of Strongbridge from July 2020 to October 2021. Since March 2022 Mr. Johnson has served as Chief Executive Officer and Director of Reaction Biology Corp., a biotechnology company. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. Mr. Johnson is also a member of the board of directors of Verastem, Inc. also known as Verastem Oncology and Autolus Therapeutics. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr.Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization.
高管简历
中英对照 | 中文 | 英文- Paul Edick
Paul Edick自2015年6月起在公司董事会工作。他目前是3G Advisors有限责任公司（3G Advisors, LLC，医药，医疗保健和医疗保健投资者团体的顾问公司，2007年创立）的经营合伙人。2010年7月-2014年11月Edick先生是Durata Therapeutics的首席执行官，2014年11月和Actavis plc NYSE： ACT合并。在那之前，Edick先生是Ganic Pharmaceuticals的首席执行官（2008-2010年）；MedPointe Healthcare 股份有限公司（MedPointe Healthcare Inc.）的首席执行官（2006-2008年）；MedPointe的药学运营总裁（2002-2006年）。Edick先生在NewLink Genetics股份有限公司（NewLink Genetics Inc. （NASDAQ： NLNK））和Circassia Ltd. （LSE： CIR.L）董事会工作（2011年起）。他拥有纽约克林顿汉弥尔顿林肯学院（Hamilton College in Clinton, NY）心理学学士学位。
Paul Edick has served as Xeris Pharmaceuticals, Inc. Chief Executive Officer since May 2021 in connection with the Strongbridge acquisition. Mr. Edick joined Xeris Pharmaceuticals, Inc. in January 2017 as President and Chief Executive Officer and was appointed as Chairman in June 2018. As of August 2020 Mr. Edick relinquished the President title he held at Xeris Pharmaceuticals, Inc. Previously, Mr. Edick was a founding partner of 3G Advisors, a consultancy firm to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014 Mr. Edick was the chief executive officer of Durata Therapeutics, Inc., a biopharmaceutical company, prior to its acquisition in November 2014. Prior to that, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from 2008 to 2010. Before that, from 2006 to 2008 Mr. Edick was chief executive officer of MedPointe Healthcare, Inc., a pharmaceutical company, and served as its president of pharmaceutical operations from 2002 to 2006.- Paul Edick自2015年6月起在公司董事会工作。他目前是3G Advisors有限责任公司（3G Advisors, LLC，医药，医疗保健和医疗保健投资者团体的顾问公司，2007年创立）的经营合伙人。2010年7月-2014年11月Edick先生是Durata Therapeutics的首席执行官，2014年11月和Actavis plc NYSE： ACT合并。在那之前，Edick先生是Ganic Pharmaceuticals的首席执行官（2008-2010年）；MedPointe Healthcare 股份有限公司（MedPointe Healthcare Inc.）的首席执行官（2006-2008年）；MedPointe的药学运营总裁（2002-2006年）。Edick先生在NewLink Genetics股份有限公司（NewLink Genetics Inc. （NASDAQ： NLNK））和Circassia Ltd. （LSE： CIR.L）董事会工作（2011年起）。他拥有纽约克林顿汉弥尔顿林肯学院（Hamilton College in Clinton, NY）心理学学士学位。
- Paul Edick has served as Xeris Pharmaceuticals, Inc. Chief Executive Officer since May 2021 in connection with the Strongbridge acquisition. Mr. Edick joined Xeris Pharmaceuticals, Inc. in January 2017 as President and Chief Executive Officer and was appointed as Chairman in June 2018. As of August 2020 Mr. Edick relinquished the President title he held at Xeris Pharmaceuticals, Inc. Previously, Mr. Edick was a founding partner of 3G Advisors, a consultancy firm to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014 Mr. Edick was the chief executive officer of Durata Therapeutics, Inc., a biopharmaceutical company, prior to its acquisition in November 2014. Prior to that, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from 2008 to 2010. Before that, from 2006 to 2008 Mr. Edick was chief executive officer of MedPointe Healthcare, Inc., a pharmaceutical company, and served as its president of pharmaceutical operations from 2002 to 2006.
- Beth Hecht
Beth Hecht， 她任职于Xeris Biopharma Holdings, Inc.董事会（2015年9月以来）。2012年10月以来，她曾担任Auven Therapeutics（全球私人股本公司，收购和开发医药产品，并解决未满足的医疗需求）的董事总经理兼首席法务和行政官。从2013年11月到2014年11月，她也曾担任Durata Therapeutics（于2014年11月与Actavis plc合并）的公司秘书、法务和合规顾问。此前，她曾担任the Sun Products Corporation的高级副总裁、总法律顾问和公司秘书（2009年3月至2012年9月），此前曾担任MedPointe Inc的执行副总裁兼总法律顾问。她持有Harvard Law School的法学博士学位，以及Amherst College的学士学位。
Beth Hecht has served as Xeris Pharmaceuticals, Inc. Chief Legal Officer and Corporate Secretary since October 2021 in connection with the Strongbridge acquisition. Ms. Hecht joined Xeris Pharmaceuticals, Inc. in January 2018 as the Senior Vice President, General Counsel and Corporate Secretary. Ms. Hecht has over twenty-five years of experience as a corporate executive in the life sciences industry, most recently serving from 2012 to 2018 as managing director and chief legal and administrative officer of Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm from 2012 to 2018. From November 2013 through November 2014 Ms. Hecht also served as corporate secretary and legal and compliance advisor at Durata Therapeutics, a biopharmaceutical company. Prior to that, she was senior vice president, general counsel and corporate secretary at the Sun Products Corporation from March 2009 through September 2012 and prior to that executive vice president and general counsel of MedPointe Healthcare, Inc., a pharmaceutical company. Since March 2021 Ms. Hecht has served on the board of directors of Iterum Therapeutics plc, a clinical stage pharmaceutical company, where she serves on the audit and compensation committees. Additionally, from September 2015 through March 2021 she served on the board of directors for Neos Therapeutics, Inc., a pharmaceutical company, where she chaired the nominating and corporate governance committee. Neos Therapeutics was acquired by Aytu Biopharma Inc. in March 2021. Ms. Hecht received a J.D. from Harvard Law School and a B.A. from Amherst College.- Beth Hecht， 她任职于Xeris Biopharma Holdings, Inc.董事会（2015年9月以来）。2012年10月以来，她曾担任Auven Therapeutics（全球私人股本公司，收购和开发医药产品，并解决未满足的医疗需求）的董事总经理兼首席法务和行政官。从2013年11月到2014年11月，她也曾担任Durata Therapeutics（于2014年11月与Actavis plc合并）的公司秘书、法务和合规顾问。此前，她曾担任the Sun Products Corporation的高级副总裁、总法律顾问和公司秘书（2009年3月至2012年9月），此前曾担任MedPointe Inc的执行副总裁兼总法律顾问。她持有Harvard Law School的法学博士学位，以及Amherst College的学士学位。
- Beth Hecht has served as Xeris Pharmaceuticals, Inc. Chief Legal Officer and Corporate Secretary since October 2021 in connection with the Strongbridge acquisition. Ms. Hecht joined Xeris Pharmaceuticals, Inc. in January 2018 as the Senior Vice President, General Counsel and Corporate Secretary. Ms. Hecht has over twenty-five years of experience as a corporate executive in the life sciences industry, most recently serving from 2012 to 2018 as managing director and chief legal and administrative officer of Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm from 2012 to 2018. From November 2013 through November 2014 Ms. Hecht also served as corporate secretary and legal and compliance advisor at Durata Therapeutics, a biopharmaceutical company. Prior to that, she was senior vice president, general counsel and corporate secretary at the Sun Products Corporation from March 2009 through September 2012 and prior to that executive vice president and general counsel of MedPointe Healthcare, Inc., a pharmaceutical company. Since March 2021 Ms. Hecht has served on the board of directors of Iterum Therapeutics plc, a clinical stage pharmaceutical company, where she serves on the audit and compensation committees. Additionally, from September 2015 through March 2021 she served on the board of directors for Neos Therapeutics, Inc., a pharmaceutical company, where she chaired the nominating and corporate governance committee. Neos Therapeutics was acquired by Aytu Biopharma Inc. in March 2021. Ms. Hecht received a J.D. from Harvard Law School and a B.A. from Amherst College.
- Steven Prestrelski
Steven Prestrelski是我们的联合创始人之一。他曾一直担任我们的首席科学官（2005年以来），以及我们的临时首席执行官（2013年至2014年）。他也曾任职我们的董事会（2005年至2015年）。Prestrelski博士是我们平台技术的发明者。在加入我们公司之前，从2003年到2011年，Prestrelski博士是Amylin Pharmaceuticals制药研发的Vice President。在Amylin，从2003年到2005年他是the Bydureon Program的执行董事。Prestrelski从1998年到2002年担任Powderject Technologies，Inc.生物制药Vice President。Prestrelski博士在Barofold，Inc.的董事会和Imedd，Inc.的科学顾问委员会任职。Prestrelski博士从2012年到2014年在GIRX Metabolics的科学咨询委员会任职。Prestrelski博士拥有德雷克塞尔大学（Drexel University）营养科学学士学位，纽约城市大学（City University of New York）分子生物物理学博士学位和加州大学圣地亚哥分校（University of California，San Diego）雷迪管理学院（Rady School of Management）工商管理硕士学位。
Steven Prestrelski has served as Xeris Pharmaceuticals, Inc. Chief Scientific Officer since October 2021 in connection with the Strongbridge acquisition. Dr. Prestrelski is the inventor of Xeris Pharmaceuticals, Inc. platform technologies. Dr. Prestrelski is one of the co-founders of Xeris Pharmaceuticals, Inc. and served as its Chief Scientific Officer since 2005 and as Interim Chief Executive Officer from 2013 to 2014. Dr. Prestrelski also served on Xeris Pharmaceuticals, Inc.'s board of directors from 2005 to 2015. Prior to joining Xeris Pharmaceuticals, Inc. company, from 2003 to 2011 Dr. Prestrelski was vice president of pharmaceutical R&D at Amylin Pharmaceuticals, a biopharmaceutical company. At Amylin, from 2005 to 2008 he was the executive director of the Bydureon® program. From 1998 to 2002 Dr. Prestrelski was vice president, biopharmaceuticals at PowderJect Technologies, Inc., a drug and diagnostics delivery company. Prior to his time at PowderJect, Dr. Prestrelski also held technical and management positions at Alza and Amgen.- Steven Prestrelski是我们的联合创始人之一。他曾一直担任我们的首席科学官（2005年以来），以及我们的临时首席执行官（2013年至2014年）。他也曾任职我们的董事会（2005年至2015年）。Prestrelski博士是我们平台技术的发明者。在加入我们公司之前，从2003年到2011年，Prestrelski博士是Amylin Pharmaceuticals制药研发的Vice President。在Amylin，从2003年到2005年他是the Bydureon Program的执行董事。Prestrelski从1998年到2002年担任Powderject Technologies，Inc.生物制药Vice President。Prestrelski博士在Barofold，Inc.的董事会和Imedd，Inc.的科学顾问委员会任职。Prestrelski博士从2012年到2014年在GIRX Metabolics的科学咨询委员会任职。Prestrelski博士拥有德雷克塞尔大学（Drexel University）营养科学学士学位，纽约城市大学（City University of New York）分子生物物理学博士学位和加州大学圣地亚哥分校（University of California，San Diego）雷迪管理学院（Rady School of Management）工商管理硕士学位。
- Steven Prestrelski has served as Xeris Pharmaceuticals, Inc. Chief Scientific Officer since October 2021 in connection with the Strongbridge acquisition. Dr. Prestrelski is the inventor of Xeris Pharmaceuticals, Inc. platform technologies. Dr. Prestrelski is one of the co-founders of Xeris Pharmaceuticals, Inc. and served as its Chief Scientific Officer since 2005 and as Interim Chief Executive Officer from 2013 to 2014. Dr. Prestrelski also served on Xeris Pharmaceuticals, Inc.'s board of directors from 2005 to 2015. Prior to joining Xeris Pharmaceuticals, Inc. company, from 2003 to 2011 Dr. Prestrelski was vice president of pharmaceutical R&D at Amylin Pharmaceuticals, a biopharmaceutical company. At Amylin, from 2005 to 2008 he was the executive director of the Bydureon® program. From 1998 to 2002 Dr. Prestrelski was vice president, biopharmaceuticals at PowderJect Technologies, Inc., a drug and diagnostics delivery company. Prior to his time at PowderJect, Dr. Prestrelski also held technical and management positions at Alza and Amgen.
- Ken Johnson
Ken Johnson于2017年3月加入我们公司。在此之前，Johnson博士于2016年至2017年担任默克医院专科产品美国医疗事务执行董事。此前，约翰逊博士曾于2015年至2016年担任Circassia Pharmaceuticals全球医疗事务Vice President，并于2012年至2015年担任Durata Therapeutics企业医疗事务Vice President。在Durata之前，Johnson先生还在Horizon Pharma，Inc.，Takeda Pharmaceuticals North America，Neopharm，Inc.，Searle/Pharmacia Pharmaceuticals和Bristol-Myers Squibb.担任医疗事务的高级管理职位。约翰逊获得了药剂学和药剂学学士学位。the University of Minnesota的博士学位，并在University of Tennessee Health Sciences Center完成博士后奖学金。
Ken Johnson has served as Xeris Pharmaceuticals, Inc. Senior Vice President, Global Development and Medical Affairs since October 2021 in connection with the Strongbridge acquisition. Dr. Johnson joined Xeris Pharmaceuticals in March 2017 as Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs. Prior to that, from 2016 to 2017 Dr. Johnson served as executive director, U.S. medical affairs for hospital specialty products at Merck, a pharmaceutical company. Previously, Dr. Johnson served as vice president of global medical affairs at Circassia Pharmaceuticals, a biopharmaceutical company, from 2015 to 2016 and as vice president of corporate medical affairs at Durata Therapeutics, a biopharmaceutical company, from 2012 to 2015. Prior to his time at Durata, Dr. Johnson also held senior management positions in medical affairs at Horizon Pharma, Inc., Takeda Pharmaceuticals North America, NeoPharm, Inc., G.D. Searle, LLC/Pharmacia Corporation and Bristol-Myers Squibb.- Ken Johnson于2017年3月加入我们公司。在此之前，Johnson博士于2016年至2017年担任默克医院专科产品美国医疗事务执行董事。此前，约翰逊博士曾于2015年至2016年担任Circassia Pharmaceuticals全球医疗事务Vice President，并于2012年至2015年担任Durata Therapeutics企业医疗事务Vice President。在Durata之前，Johnson先生还在Horizon Pharma，Inc.，Takeda Pharmaceuticals North America，Neopharm，Inc.，Searle/Pharmacia Pharmaceuticals和Bristol-Myers Squibb.担任医疗事务的高级管理职位。约翰逊获得了药剂学和药剂学学士学位。the University of Minnesota的博士学位，并在University of Tennessee Health Sciences Center完成博士后奖学金。
- Ken Johnson has served as Xeris Pharmaceuticals, Inc. Senior Vice President, Global Development and Medical Affairs since October 2021 in connection with the Strongbridge acquisition. Dr. Johnson joined Xeris Pharmaceuticals in March 2017 as Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs. Prior to that, from 2016 to 2017 Dr. Johnson served as executive director, U.S. medical affairs for hospital specialty products at Merck, a pharmaceutical company. Previously, Dr. Johnson served as vice president of global medical affairs at Circassia Pharmaceuticals, a biopharmaceutical company, from 2015 to 2016 and as vice president of corporate medical affairs at Durata Therapeutics, a biopharmaceutical company, from 2012 to 2015. Prior to his time at Durata, Dr. Johnson also held senior management positions in medical affairs at Horizon Pharma, Inc., Takeda Pharmaceuticals North America, NeoPharm, Inc., G.D. Searle, LLC/Pharmacia Corporation and Bristol-Myers Squibb.
- Steven M. Pieper
Steven M. Pieper自2021年10月起担任Xeris Pharmaceuticals, Inc.首席财务官，参与对Strongbridge的收购。Pieper先生于2017年2月加入Xeris Pharmaceuticals，Inc.，担任财务副总裁，并于2021年7月被任命为0。此前，从2015年7月到2017年2月，Pieper先生在Catheter Connections，Inc.担任越来越多的职责，包括最近担任首席财务官和首席运营官。
Steven M. Pieper has served as Xeris Pharmaceuticals, Inc. Chief Financial Officer since October 2021 in connection with the Strongbridge acquisition. Mr. Pieper joined Xeris Pharmaceuticals, Inc. in February 2017 as vice president of finance and was appointed as Chief Financial Officer in July 2021. Previously, from July 2015 to February 2017 Mr. Pieper held roles of increasing responsibility at Catheter Connections, Inc., including most recently as chief financial officer and chief operating officer.- Steven M. Pieper自2021年10月起担任Xeris Pharmaceuticals, Inc.首席财务官，参与对Strongbridge的收购。Pieper先生于2017年2月加入Xeris Pharmaceuticals，Inc.，担任财务副总裁，并于2021年7月被任命为0。此前，从2015年7月到2017年2月，Pieper先生在Catheter Connections，Inc.担任越来越多的职责，包括最近担任首席财务官和首席运营官。
- Steven M. Pieper has served as Xeris Pharmaceuticals, Inc. Chief Financial Officer since October 2021 in connection with the Strongbridge acquisition. Mr. Pieper joined Xeris Pharmaceuticals, Inc. in February 2017 as vice president of finance and was appointed as Chief Financial Officer in July 2021. Previously, from July 2015 to February 2017 Mr. Pieper held roles of increasing responsibility at Catheter Connections, Inc., including most recently as chief financial officer and chief operating officer.
- John Shannon
John Shannon于2017年2月加入我们公司，担任首席运营官。此前，从2015年到2016年被收购，Shannon先生担任Catheter Connections，Inc.的首席执行官兼董事。在此之前，从2012年到2014年被收购，Shannon先生担任Durata Therapeutics的首席商务官。从2002年到2012年，他担任Baxter Bioscience的Vice President和总经理。Shannon获得Western Illinois University生物学B.S.学位，重点是微生物学。
John Shannon has served as Xeris Pharmaceuticals, Inc. President and Chief Operating Officer since October 2021 in connection with the Strongbridge acquisition. Mr. Shannon joined Xeris Pharmaceuticals, Inc. in February 2017 as Chief Operating Officer and in August 2020 Mr. Shannon was appointed President of Xeris Pharmaceuticals, Inc. as well. Previously, from 2015 until its acquisition in 2016 Mr. Shannon served as chief executive officer and director for Catheter Connections, Inc. Prior to that, from 2012 until its acquisition in 2014 Mr. Shannon served as chief commercial officer for Durata Therapeutics, a biopharmaceutical company. From 2002 to 2012 he served as vice president and general manager of Baxter BioScience, a biopharmaceutical company.- John Shannon于2017年2月加入我们公司，担任首席运营官。此前，从2015年到2016年被收购，Shannon先生担任Catheter Connections，Inc.的首席执行官兼董事。在此之前，从2012年到2014年被收购，Shannon先生担任Durata Therapeutics的首席商务官。从2002年到2012年，他担任Baxter Bioscience的Vice President和总经理。Shannon获得Western Illinois University生物学B.S.学位，重点是微生物学。
- John Shannon has served as Xeris Pharmaceuticals, Inc. President and Chief Operating Officer since October 2021 in connection with the Strongbridge acquisition. Mr. Shannon joined Xeris Pharmaceuticals, Inc. in February 2017 as Chief Operating Officer and in August 2020 Mr. Shannon was appointed President of Xeris Pharmaceuticals, Inc. as well. Previously, from 2015 until its acquisition in 2016 Mr. Shannon served as chief executive officer and director for Catheter Connections, Inc. Prior to that, from 2012 until its acquisition in 2014 Mr. Shannon served as chief commercial officer for Durata Therapeutics, a biopharmaceutical company. From 2002 to 2012 he served as vice president and general manager of Baxter BioScience, a biopharmaceutical company.